Trial reportLasers in medical science2025
Efficacy of 450-nm blue laser-mediated aminolevulinic acid photodynamic therapy for plaque psoriasis: a prospective self-controlled clinical trial.
Trial report in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthetic Curcuminoids Combined with Blue-Light-Mediated Photodynamic Therapy for Anti-Inflammatory Effect and Potential Mechanism on Imiquimod-Induced Psoriasis-like Proliferation of Keratinocytes.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This self-controlled prospective study evaluated the efficacy and safety of 450 nm blue laser-mediated aminolevulinic acid photodynamic therapy (ALA-BL-PDT) in 28 patients with plaque psoriasis. Participants received four treatment sessions at two-week intervals. At two weeks post-treatment, 67.9% (19/28) achieved Physician Global Assessment (PGA) scores of 0 or 1 (clear or almost clear). Treatment response correlated significantly with baseline disease severity, with higher efficacy observed in patients with body surface area (BSA) ≤ 5% (84.2%) and Psoriasis Area and Severity Index (PASI) ≤ 5 (86.7%) (both p < 0.05). Treatment-associated pain was well-tolerated and decreased significantly after the first session. The one-year recurrence rate among responders was 47.4% (9/19). These preliminary results suggest ALA-BL-PDT may be effective and well-tolerated treatment for mild-to-moderate plaque psoriasis, though larger randomized controlled trials are needed for validation.
Indexed as
Identifiers
41354718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.